

May 18, 2022

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
--	--

Dear Sir/Madam,

Sub: Unit 5 - US FDA Inspection – Reg.,

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we submit the following:

As already informed in the earnings call in Feb 22, the Pre-approval inspection was carried out during the period 8th Feb '22 to 15th Feb '22. On completion of the inspection, Form 483 was issued with 5 observations. Based on the inspection review and the written responses provided by the Company, the Agency has concluded that the assessment is completed with 'no remaining deficiencies'. A copy of the EIR has been received dated 17th May 2022.

Please take the information on record.

Thanking you,

Yours faithfully,
For AUROBINDO PHARMA LIMITED



B. Adi Reddy
Company Secretary

